Renal cell carcinoma · line 1 · Cabozantinib monotherapy (RCC, 2L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CABOZANTINIB-RCC |
| ID | IND-RCC-NON-CLEAR-CELL-1L-CABOZANTINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Non-clear-cell RCC is a heterogeneous group; this indication covers the common case of papillary/MET-driven subtype where cabozantinib is NCCN-preferred. For chromophobe RCC, clinical trial is preferred. For collecting duct / medullary RCC, platinum-based chemotherapy ± ICI is preferred (separate indication needed). BIO-MET amplification/activating mutation identifies the MET-driven papillary type-1 subset with strongest cabozantinib rationale.
Used By
No reverse references found in the YAML corpus.